Actavis Follows Up On Pull-Out Threat, Sells China Unit To Zhejiang Chiral
This article was originally published in PharmAsia News
Executive Summary
Actavis followed through on its earlier threat to pull out of "too risky" China by selling its Actavis (Foshan) Pharmaceutical subsidiary to Zhejiang Chiral Medicine Chemicals for an undisclosed amount.